2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Fabry Disease: new trials by email Literature Review of Fabry Disease trials Research Report on Fabry Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Replagal in Treatment-naïve Adults With Fabry Disease REPLAGAL - Fabry Disease | Phase 3 | Terminated | Shire | 17 | 2021-12-28 | 2024-06-17 |
| Open-Label Phase 3 Long-Term Safety Study of Migalastat migalastat hydrochloride - Fabry Disease | Phase 3 | Terminated | Amicus Therapeutics | 85 | 2011-10-14 | 2018-10-02 |
Brain Diseases (2) · Brain Diseases, Metabolic (2) · Brain Diseases, Metabolic, Inborn (2) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Cerebral Small Vessel Diseases (2) · Cerebrovascular Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Lipid Metabolism Disorders (2) · Lipid Metabolism, Inborn Errors (2) · Lipidoses (2) · Lysosomal Storage Diseases (2) · Lysosomal Storage Diseases, Nervous System (2)
agalsidase alfa (1) · larazotide acetate (1) · migalastat (1)
Amicus Therapeutics (1) · Shire (1)
Canada (2) · Spain (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Denmark (1) · Egypt (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Poland (1) · Portugal (1)
2018 (1)